ARE PLEASED TO ANNOUNCE THE WORLD FIRST MARKET AUTHORISATION FOR A DONOR-DERIVED MICROBIOME-BASED PRODUCT
Using the microbiome to treat disease
Who are you?
Treatments driven by science
BiomeBank is on a mission to discover and develop new microbiome-based therapies that will treat a number of chronic diseases with unmet medical need.
In partnership with world-leading organisations running large-phased clinical studies, BiomeBank is building a pipeline of microbiome-based therapies to treat diseases ranging from recurrent clostridioides difficile infection (C.difficile), to Ulcerative Colitis and Crohn’s disease.
Our team of translational microbiome experts have developed a unique platform which combines the capabilities of machine learning and microbiology to inform microbiome drug discovery and development.
We currently supply a donor derived microbiome-based therapy used by doctors and hospitals to treat recurrent C.difficile infection.
BiomeBank's pioneering research has been published in these leading medical journals:
Latest news
Long reads
Get a better understanding of your microbiome with our long read articles.
BiomeBank has been featured by:
The gut microbiome is the community of organisms that live in your intestinal tract. In fact, trillions of microbes call the human gut home. Although one single microbe is harmless, vast communities of different species together carry important functions for maintaining health, similar to an organ. Loss of function can lead to chronic disease.
In recent years new technology has enabled scientists to culture and analyse the DNA of these complex communities. This has paved the way for new breakthroughs in the treatment of chronic disease where the traditional approach of drugs and surgeries are proving inadequate.
We are a multidisciplinary team of research scientists and drug development experts who are at the forefront of microbiome research, looking to discover and develop microbiome-based therapies.
The translation of research into the development of innovative and life-saving microbiome-based therapies are further bolstered by BiomeBank’s partnership with world-leading biomedical research organisations. This includes RMIT University, Hudson Institute of Medical Research, and Hospital Networks globally.